This website is intended for US Healthcare Professionals.
This website is intended for US Healthcare Professionals.
Request a RepINDICATIONS
REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.
REBLOZYL® (luspatercept-aamt) is indicated for the treatment of anemia failing an erythropoiesis stimulating agent and requiring 2 or more red blood cell (RBC) units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T).
REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.
Request a Rep
Dosing and Administration: Dosing calculator
Please enter your patient's weight (age 18+):
Type of dose:
Current dose
Current dose
Adverse reaction
Do not continue treatment or increase dose if patient is experiencing unacceptable toxicity or any adverse event. Do not increase dose more frequently than every 6 weeks (2 doses): do not increase dose beyond maximum dose.
Insufficient response is defined as not RBC transfusion-free after at least 2 consecutive doses (6 weeks) at the current dose (for the 1.0 mg/kg and 1.33 mg/kg dose levels), or no reduction in RBC transfusion burden after 3 consecutive doses (9 weeks) at 1.75 mg/kg.
- Not RBC transfusion-free after ≥2 consecutive doses at the 1 mg/kg and 1.33 mg/kg dose levels
- No reduction in transfusion burden after ≥3 doses (9 weeks) at the 1.75 mg/kg dose level
For dose decrease for increase in Hgb only: Initiate a dose decrease if there is an increase in patient's Hgb by >2 g/dL within 3 weeks in the absence of transfusions.
Please enter a weight between 74 lb and 337 lb.
Dosing for: MDS-associated anemia
REBLOZYL does not have a weight restriction per the Prescribing Information. The maximum studied weight in the MEDALIST trial was 337 lb. 168 mg was the maximum dose permitted in the MEDALIST trial. Please consult the Prescribing Information for complete dosing instructions.
Discontinue REBLOZYL if a patient does not experience clinical benefit, ie, a decrease in transfusion burden including no increase from baseline hemoglobin after 9 weeks of treatment (administration of 3 doses) at the maximum dose level (1.75 mg/kg) or if unacceptable toxicity occurs at any time.
DISCONTINUE REBLOZYL.
DISCONTINUE REBLOZYL.
Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, and Grade 4 is life-threatening.
INTERRUPT treatment and RESTART REBLOZYL at the next lower dose level when the adverse reaction resolves to no more than Grade 1*
Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, and Grade 4 is life-threatening.
*If dose delay is >12 consecutive weeks, discontinue treatment. Follow dose decrease instructions for increase in Hgb or adverse reaction that resolved to Grade 1.
PATIENT WEIGHT
[––]
STARTING DOSE
(1 mg/kg)
(1 mg/kg)
[––]
RECONSTITUTED VOLUME
[––]
Prior to each REBLOZYL administration, assess if patient may require a dose adjustment. Review Hgb prior to administration. If RBC transfusion occurred, use pretransfusion Hgb.
Divide doses requiring larger reconstituted volumes (ie, >1.2 mL) into separate, similar-volume injections and inject into separate sites.
By using this resource, you agree to the following: This dosing calculator is being provided "AS IS" and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Bristol Myers Squibb makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Bristol Myers Squibb, nor any other party involved in the preparation or publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information.
Hgb=hemoglobin; MDS=myelodysplastic syndromes; RBC=red blood cell; SC=subcutaneous.
Dosing and Administration: Dosing calculator
Please enter your patient's weight (age 18+):
Type of dose:
Current dose
Current dose
Adverse reaction
Do not continue treatment or increase dose if patient is experiencing unacceptable toxicity or any adverse event. Do not increase dose more frequently than every 6 weeks (2 doses): do not increase dose beyond maximum dose.
Insufficient response is defined as not RBC transfusion-free after at least 2 consecutive doses (6 weeks) at the current dose (for the 1.0 mg/kg and 1.33 mg/kg dose levels), or no reduction in RBC transfusion burden after 3 consecutive doses (9 weeks) at 1.75 mg/kg.
- Not RBC transfusion-free after ≥2 consecutive doses at the 1 mg/kg and 1.33 mg/kg dose levels
- No reduction in transfusion burden after ≥3 doses (9 weeks) at the 1.75 mg/kg dose level
For dose decrease for increase in Hgb only: Initiate a dose decrease if there is an increase in patient's Hgb by >2 g/dL within 3 weeks in the absence of transfusions.
Please enter a weight between 74 lb and 337 lb.
Dosing for: MDS-associated anemia
REBLOZYL does not have a weight restriction per the Prescribing Information. The maximum studied weight in the MEDALIST trial was 337 lb. 168 mg was the maximum dose permitted in the MEDALIST trial. Please consult the Prescribing Information for complete dosing instructions.
Discontinue REBLOZYL if a patient does not experience clinical benefit, ie, a decrease in transfusion burden including no increase from baseline hemoglobin after 9 weeks of treatment (administration of 3 doses) at the maximum dose level (1.75 mg/kg) or if unacceptable toxicity occurs at any time.
DISCONTINUE REBLOZYL.
DISCONTINUE REBLOZYL.
Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, and Grade 4 is life-threatening.
INTERRUPT treatment and RESTART REBLOZYL at the next lower dose level when the adverse reaction resolves to no more than Grade 1*
Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe, and Grade 4 is life-threatening.
*If dose delay is >12 consecutive weeks, discontinue treatment. Follow dose decrease instructions for increase in Hgb or adverse reaction that resolved to Grade 1.
PATIENT WEIGHT
[––]
STARTING DOSE
(1 mg/kg)
(1 mg/kg)
[––]
RECONSTITUTED VOLUME
[––]
Prior to each REBLOZYL administration, assess if patient may require a dose adjustment. Review Hgb prior to administration. If RBC transfusion occurred, use pretransfusion Hgb.
Divide doses requiring larger reconstituted volumes (ie, >1.2 mL) into separate, similar-volume injections and inject into separate sites.
By using this resource, you agree to the following: This dosing calculator is being provided "AS IS" and is intended for use only by qualified healthcare providers. All calculations should be confirmed before use. Bristol Myers Squibb makes no claims as to the accuracy of the information contained herein. The information being provided is not a substitute for clinical judgment. Neither Bristol Myers Squibb, nor any other party involved in the preparation or publication of this site, shall be liable to you or others for any decisions made or actions taken by you or others in reliance on this information.
Hgb=hemoglobin; MDS=myelodysplastic syndromes; RBC=red blood cell; SC=subcutaneous.